[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] HANAHAN D, COUSSENS L M. Accessories to the crime: functions of cells recruited to the tumor microenvironment[J]. Cancer Cell, 2012, 21(3): 309-322. doi:  10.1016/j.ccr.2012.02.022
[3] ACHARYA P, CHOUHAN K, WEISKIRCHEN S, et al. Cellular Mechanisms of Liver Fibrosis[J]. Front Pharmacol, 2021, 12: 671640. doi:  10.3389/fphar.2021.671640
[4] FILLIOL A, SAITO Y, NAIR A, et al. Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis[J]. Nature, 2022, 610(7931): 356-365. doi:  10.1038/s41586-022-05289-6
[5] BIFFI G, TUVESON D A. Diversity and Biology of Cancer-Associated Fibroblasts[J]. Physiol Rev, 2021, 101(1): 147-176. doi:  10.1152/physrev.00048.2019
[6] COGLIATI B, YASHASWINI C N, WANG S, et al. Friend or foe? The elusive role of hepatic stellate cells in liver cancer[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(10): 647-661. doi:  10.1038/s41575-023-00821-z
[7] LI J, LIU X G, GE R L, et al. The ligation between ERMAP, galectin-9 and dectin-2 promotes Kupffer cell phagocytosis and antitumor immunity[J]. Nat Immunol, 2023, 24(11): 1813-1824. doi:  10.1038/s41590-023-01634-7
[8] HAO X, SUN G, ZHANG Y, et al. Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges[J]. Front Cell Dev Biol, 2021, 9: 775462. doi:  10.3389/fcell.2021.775462
[9] LI X, RAMADORI P, PFISTER D, et al. The immunological and metabolic landscape in primary and metastatic liver cancer[J]. Nat Rev Cancer, 2021, 21(9): 541-557. doi:  10.1038/s41568-021-00383-9
[10] MALEHMIR M, PFISTER D, GALLAGE S, et al. Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer[J]. Nat Med, 2019, 25(4): 641-655. doi:  10.1038/s41591-019-0379-5
[11] CHEN K J, LIN S Z, ZHOU L, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis[J]. PLoS One, 2011, 6(9): e24671. doi:  10.1371/journal.pone.0024671
[12] LANGHANS B, NISCHALKE H D, KRAMER B, et al. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2019, 68(12): 2055-2066. doi:  10.1007/s00262-019-02427-4
[13] CHEW V, TOW C, TEO M, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients[J]. J Hepatol, 2010, 52(3): 370-379. doi:  10.1016/j.jhep.2009.07.013
[14] OURA K, MORISHITA A, TANI J, et al. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review[J]. Int J Mol Sci, 2021, 22(11).
[15] KONG L Q, ZHU X D, XU H X, et al. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma[J]. PLoS One, 2013, 8(3): e59771. doi:  10.1371/journal.pone.0059771
[16] VEGLIA F, PEREGO M, GABRILOVICH D. Myeloid-derived suppressor cells coming of age[J]. Nat Immunol, 2018, 19(2): 108-119. doi:  10.1038/s41590-017-0022-x
[17] KAPANADZE T, GAMREKELASHVILI J, MA C, et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma[J]. J Hepatol, 2013, 59(5): 1007-1013. doi:  10.1016/j.jhep.2013.06.010
[18] HOECHST B, VOIGTLAENDER T, ORMANDY L, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor[J]. Hepatology, 2009, 50(3): 799-807. doi:  10.1002/hep.23054
[19] COFFELT S B, WELLENSTEIN M D, de VISSER K E. Neutrophils in cancer: neutral no more[J]. Nat Rev Cancer, 2016, 16(7): 431-446. doi:  10.1038/nrc.2016.52
[20] LIU K, WANG F S, XU R. Neutrophils in liver diseases: pathogenesis and therapeutic targets[J]. Cell Mol Immunol, 2021, 18(1): 38-44. doi:  10.1038/s41423-020-00560-0
[21] CHEN L, GU J, QIAN Y, et al. Deletion of C-C Motif Chemokine Ligand 5 Worsens Invariant Natural Killer T-Cell-Mediated Hepatitis via Compensatory Up-regulation of CXCR2-Related Chemokine Activity[J]. Cell Mol Gastroenterol Hepatol, 2019, 7(3): 623-639. doi:  10.1016/j.jcmgh.2018.12.009
[22] SCHEINER B, KIRSTEIN M, POPP S, et al. Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma[J]. Liver Cancer, 2019, 8(3): 203-217. doi:  10.1159/000489833
[23] POUJOL-ROBERT A, BOELLE P Y, CONTI F, et al. Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation[J]. Clin Res Hepatol Gastroenterol, 2014, 38(5): 570-576. doi:  10.1016/j.clinre.2014.07.004
[24] CARR B I, GUERRA V. Thrombocytosis and hepatocellular carcinoma[J]. Dig Dis Sci, 2013, 58(6): 1790-1796. doi:  10.1007/s10620-012-2527-3
[25] MA C, FU Q, DIGGS L P, et al. Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD[J]. Cancer Cell, 2022, 40(9): 986-998. doi:  10.1016/j.ccell.2022.08.004
[26] MA H P, CHANG H L, BAMODU O A, et al. Collagen 1A1(COL1A1)Is a Reliable Biomarker and Putative Therapeutic Target for Hepatocellular Carcinogenesis and Metastasis[J]. Cancers(Basel), 2019, 11(6).
[27] MUSTONEN A M, SALVEN A, KARJA V, et al. Hyaluronan histochemistry-a potential new tool to assess the progress of liver disease from simple steatosis to hepatocellular carcinoma[J]. Glycobiology, 2019, 29(4): 298-306. doi:  10.1093/glycob/cwz002
[28] TANAKA Y, TATEISHI R, KOIKE K. Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma[J]. Int J Mol Sci, 2018, 19(10).
[29] YOU Y, ZHENG Q, DONG Y, et al. Higher Matrix Stiffness Upregulates Osteopontin Expression in Hepatocellular Carcinoma Cells Mediated by Integrin beta1/GSK3beta/beta-Catenin Signaling Pathway[J]. PLoS One, 2015, 10(8): e134243.
[30] SCHEAU C, BADARAU I A, COSTACHE R, et al. The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma[J]. Anal Cell Pathol(Amst), 2019, 2019: 9423907.